natgillin/translations-raw huggingface dataset:
• Ringer-Lactate solution for injection.
• raztopina Ringerjevega laktata za injiciranje.
In surgery studies in which parecoxib was administered pre-operatively, no evidence of pharmacodynamic interaction was observed in patients receiving parecoxib and the inhalation anaesthetic agents nitrous oxide and isoflurane (see section
V kirurških študijah, v katerih so parekoksib uporabili pred operacijo, pri bolnikih, ki so dobivali parekoksib in inhalacijska anestetika dušikov oksid in izofluran, niso ugotovili nobenih farmakodinamičnih interakcij (glejte poglavje 5.1).
Caution should be exercised when coadministering Dynastat with warfarin and other oral anticoagulants (see section 4.5).
Pri sočasni uporabi zdravila Dynastat in varfarina ali drugih peroralnih antikoagulantov je potrebna previdnost (glejte poglavje 4.5).
COX-2 inhibitors have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term.
Dolgotrajna uporaba zaviralcev COX-2 je bila povezana s povečanim tveganjem za srčnožilne in trombotične neželene dogodke.
Plasma protein binding is approximately 98% over the concentration range achieved with the highest recommended dose, 80 mg/day.
V koncentracijskem območju, doseženem z največjim priporočenim odmerkom 80 mg/dan, je vezava na beljakovine v plazmi približno 98 %.
VIAL LABEL: 40 mg
NALEPKA NA VIALI: 40 mg
Dynastat has been studied in dental, orthopaedic, gynaecologic (principally hysterectomy) and coronary artery bypass graft surgery.
Zdravilo Dynastat so preučevali pri stomatoloških, ortopedskih in ginekoloških (predvsem histerektomiji) operacijah in obvodni operaciji koronarnih arterij.
The reconstituted solution must not be used if discoloured or cloudy or if particulate matter is observed.
Rekonstituirane raztopine ne smete uporabiti, če je obarvana, motna ali so v njej delci.
What Dynastat contains - The active substance is parecoxib (as parecoxib sodium).
Kaj vsebuje zdravilo Dynastat - Učinkovina je parekoksib (v obliki natrijevega parekoksibata).
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV lines delivering:
Po rekonstituciji z dovoljenim vehiklom smemo zdravilo Dynastat injicirati samo intravensko ali intramuskularno, ali v intravensko pot, po kateri teče:
When reconstituted in sodium chloride 9 mg/ml (0.9%) solution, Dynastat contains approximately 0.44 mmol of sodium per vial.
Po rekonstituciji z 9 mg/ml (0,9 %) raztopino natrijevega klorida vsebuje zdravilo Dynastat približno 0,44 mmol natrija na vialo.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulfonamide moiety.
Izločanje valdekoksiba poteka z obsežno presnovo v jetrih, ki vključuje več poti, med drugim izoencima CYP3A4 in CYP2C9 citokroma P450
In isolated cases, an aggravation of soft tissue infections has been described in connection with the use of NSAIDs and in nonclinical studies with Dynastat (see section 5.3).
Pri posameznikih so v zvezi z nesteroidnimi protivnetnimi zdravili in v nekliničnih študijah z zdravilom Dynastat opisali poslabšanje okužbe mehkih tkiv (glejte poglavje 5.3).
Caution is advised in the treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding, or patients using acetylsalicylic acid concomitantly.
Med zdravljenjem je potrebna previdnost pri bolnikih, ki jih ob uporabi nesteroidnih protivnetnih zdravil najbolj ogrožajo zapleti na prebavilih, pri starejših, pri bolnikih z anamnezo bolezni prebavil, npr. razjedami ali krvavitvami v prebavilih, ali pri bolnikih, ki sočasno jemljejo acetilsalicilno kislino.
or patients who may be predisposed to fluid retention, parecoxib should be initiated at the lowest recommended dose (20 mg) and the patient's kidney function should be closely monitored (see sections 4.4 and 5.2).
Bolnikom s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) ali bolnikom, nagnjenim k zastoju tekočine, je treba parekoksib uvesti v najmanjšem priporočenem odmerku (20 mg), bolnikovo delovanje ledvic pa je treba natančno nadzirati (glejte poglavji 4.4 in 5.2).
Additionally, coadministration of valdecoxib had no clinically significant effect on the hepatic or intestinal CYP 3A4-mediated metabolism of orally administered midazolam.
Poleg tega sočasna uporaba valdekoksiba ni klinično pomembno vplivala na jetrno ali črevesno presnovo (posredovano s CYP3A4) peroralno uporabljenega midazolama.
Dynastat had no effect on acetylsalicylic acid-mediated inhibition of platelet aggregation or bleeding times.
Zdravilo Dynastat ne vpliva na zavrtje agregacije trombocitov ali čas krvavitev, povezanih z acetilsalicilno kislino.
5 vials and 5 solvent ampoules
5 vial s praškom in 5 ampul z vehiklom
1 vial and 1 solvent ampoule
1 viala s praškom in 1 ampula z vehiklom
Intravenous or intramuscular use
samo za enkratno uporabo za intravensko ali intramuskularno uporabo
Rare (1/10,000 to <1/1000)
Redki ( 1/10.000 do
Serious skin reactions are known to occur with NSAIDs including COX-2 selective inhibitors as well as other medicinal products.
Znano je, da se med uporabo nesteroidnih protivnetnih zdravil, vključno s selektivnimi zaviralci COX-2, in tudi drugih zdravil pojavljajo resne kožne reakcije.
Reporting of overdose with parecoxib has been associated with adverse reactions which have also been described with recommended doses of parecoxib.
Neželeni učinki iz poročil o prekomernem odmerjanju parekoksiba so bili opisani tudi pri uporabi priporočenih odmerkov parekosiba.
Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.
Bolniki so pred randomizacijo in ves čas obeh študij obvodne operacije koronarnih arterij dobivali nizek odmerek acetilsalicilne kisline.
COX-2 inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.
Acetilsalicilna kislina in druga nesteroidna protivnetna zdravila Ker zaviralci COX-2 nimajo antiagregacijskega delovanja, niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombemboličnih bolezni.
Solvent for Dynastat 40 mg
vehikel za Dynastat 40 mg
After reconstitution with 2 ml of solvent, the concentration of parecoxib is 20 mg/ml.
Po rekonstituciji z 2 ml vehikla znaša koncentracija parekoksiba 20 mg/ml.
The following adverse reactions were reported for patients who received parecoxib (N=5,402) in 28 placebo-controlled clinical trials.
V 28 s placebom nadzorovanih kliničnih preskušanjih so poročali o naslednjih neželenih učinkih pri bolnikih, ki so prejemali parekoksib (N = 5.402).
C.
I.m.
Talk to your doctor or nurse before using Dynastat:
Pred začetkom uporabe zdravila Dynastat se posvetujte z zdravnikom ali medicinsko sestro:
Parecoxib administered intravenously to lactating rats as a single dose showed concentrations of parecoxib, valdecoxib and a valdecoxib active metabolite in milk similar to that of maternal plasma.
Po aplikaciji enkratnega intravenskega odmerka parekoksiba doječim podganam so se parekoksib, valdekoksib in aktivni presnovek valdekoksiba v mleku pojavili v podobni koncentraciji, kot v plazmi doječe podgane.
However, for elderly patients weighing less than 50 kg, treatment should be initiated with half the usual recommended dose of Dynastat and reduce the maximum daily dose to 40 mg (see section 5.2).
Starejšim bolnikom (≥ 65 let) odmerka praviloma ni treba prilagajati; če pa tehtajo manj kot 50 kg, pa je treba zdravljenje kljub temu začeti s polovičnim običajnim priporočenim odmerkom zdravila Dynastat, maksimalni dnevni odmerek pa zmanjšati na 40 mg (glejte poglavje 5.2).
Parecoxib is a prodrug of valdecoxib.
Parekoksib je predzdravilo valdekoksiba.
Asthenia, injection site pain, injection site reaction
• bolečina na mestu injiciranja ali reakcija na mestu injiciranja
Gastrointestinal disorders Nausea Abdominal pain, vomiting, constipation, dyspepsia, flatulence
Bolezni prebavil Navzea Bolečina v trebuhu, bruhanje, zaprtost, dispepsija, flatulenca
Remove the purple flip-off cap to expose the central portion of the rubber stopper of the 40 mg parecoxib vial.
Odstranite vijolično pretržno zaporko, da boste razkrili osrednji del gumijastega zamaška viale s 40 mg parekoksiba.
Pregnancy, breast-feeding and fertility ▪ If you are pregnant or trying to become pregnant, tell your doctor.
• Če ste noseči ali poizkušate zanositi, to povejte zdravniku.
Adequate monitoring of methotrexate-related toxicity should be considered when coadministering parecoxib and methotrexate.
Med sočasno uporabo parekoksiba in metotreksata je zato treba razmisliti o ustreznem spremljanju z metotreksatom povezanih toksičnih učinkov.
No effects of parecoxib on male or female fertilities were found in rats.
Pri podganah niso ugotovili, da bi parekoksib vplival na plodnost samcev ali samic.
Powder for solution for injection
prašek za raztopino za injiciranje
Additionally, fatal reports of toxic epidermal necrolysis have been reported through postmarketing surveillance in patients receiving valdecoxib (the active metabolite of parecoxib) and cannot be ruled out for parecoxib (see section 4.8).
Dodatno so v študijah v obdobju trženja pri bolnikih, ki so prejemali valdekoksib (aktivni presnovek parekoksiba), poročali o toksični epidermalni nekrolizi s smrtnim izidom; pojava le-teh ni mogoče izključiti pri uporabi parekoksiba (glejte poglavje 4.8).
Type I colourless glass vials (5 ml) with a butyl rubber stopper, sealed with a purple polypropylene flip-off cap on the aluminium overseal.
5 ml steklene viale iz brezbarvnega stekla tipa I z zamaškom iz butilne gume, zaščitenim s prevleko iz aluminija, ki ima na sredini vijolično polipropilensko pretržno zaporko, ki se odstrani na poteg.
There were no significant differences in the overall safety profile, including the four pre-specified event categories described above for the second CABG surgery study, for parecoxib/valdecoxib compared to placebo treatment in these post-surgical patients.
Pri bolnikih po prestani operaciji pri prejemanju parekoksiba/valdekoksiba v primerjavi s prejemanjem placeba niso zaznali nobenih pomembnih razlik v splošnem varnostnem profilu, vključno s predhodno določenimi štirimi kategorijami v zvezi z drugo študijo operacije CABG, ki so opisane zgoraj.
Exposure to parecoxib was similar after IV or IM administration in terms of AUC.
Izpostavljenost parekoksibu je bila glede na AUC po intravenski in intramuskularni uporabi podobna.
Fluid retention, oedema, renal
Zastajanje tekočine, edemi, ledvica
Valdecoxib is a selective COX-2 inhibitor within the clinical dose range.
Valdekoksib v območju kliničnih odmerkov selektivno zavira COX-2.
Hydrochloric acid or sodium hydroxide (for pH adjustment) Water for injection.
Vehikel natrijev klorid klorovodikova kislina ali natrijev hidroksid (za uravnavanje pH) voda za injekcije
3 vials and 3 solvent ampoules
3 viale s praškom in 3 ampule z vehiklom
Each 2 ml of reconstituted powder contains 40 mg of parecoxib.
2 ml rekonstituiranega praška vsebuje 40 mg parekoksiba.
The recommended dose is 40 mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg/day.
), ter nato vsakih 6 do 12 ur 20 mg ali 40 mg, glede na potrebo, vendar ne več kot 80 mg/dan.
After reconstitution, the concentration of parecoxib is 20 mg/ml.
Koncentracija parekoksiba po rekonstituciji je 20 mg/ml.
Use of Ringer-Lactate solution for injection or glucose 50 mg/ml (5%) in Ringer Lactate solution for injection for reconstitution will cause the parecoxib to precipitate from solution and therefore is not recommended.
Rekonstitucija raztopine natrijevega parekoksibata z uporabo raztopine Ringerjevega laktata za injiciranje ali 50 mg/ml (5 %) glukoze v raztopini Ringerjevega laktata za injiciranje povzroči precipitacijo parekoksiba iz raztopine in zato ni priporočljiva.
- If you get any side effects, talk to your doctor or nurse.
- Če opazite katerikoli neželeni učinek, se posvetujte z zdravnikom ali medicinsko sestro.
Hypersensitivity reactions (anaphylaxis and angioedema) have been reported in post-marketing experience with valdecoxib and parecoxib (see section 4.8).
Med izkušnjami z valdekoksibom in parekoksibom so v obdobju trženja poročali o preobčutljivostnih reakcijah (anafilaksa in angioedem) (glejte poglavje 4.8).
If any of these applies to you, you will not be given the injection.
Če karkoli od naštetega velja za vas, injekcije ne boste dobili, zato morate o tem nemudoma obvestiti zdravnika ali medicinsko sestro.
Serious skin reactions, including erythema multiforme, exfoliative dermatitis and Stevens-Johnson syndrome (some of them fatal) have been reported through post-marketing surveillance in patients receiving parecoxib.
V študijah v obdobju trženja so pri bolnikih, ki so prejemali parekoksib, poročali o hudih kožnih reakcijah, vključno z multiformnim eritemom, eksfoliativnim dermatitisom in Stevens-Johnsonovim sindromom (nekateri s smrtnim izidom).
As the cardiovascular risk of cyclooxygenase-2 (COX-2) specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Kardiovaskularno tveganje zaradi specifičnih zaviralcev ciklooksigenaze-2 (COX-2) se lahko poveča s povečevanjem odmerka in s trajanjem izpostavljenosti zdravilu.
Pancreatitis, oesophagitis, oedema mouth (perioral swelling)
Pankreatitis, ezofagitis, edem ust (perioralna oteklina)
Acute renal failure has been reported through post-marketing surveillance in patients receiving parecoxib (see section 4.8).
Med študijami v obdobju trženja so pri bolnikih, ki so prejemali parekoksib, poročali o akutni odpovedi ledvic (glejte poglavje 4.8).
Opioid-sparing effects
Učinek manjše uporabe opioidov
Of the patients treated with placebo, 270 patients received placebo for up to 4 days, 43 patients for up to 5 days, while only 3 patients were treated for up to 6 days and 2 patients for 7 or more days.
43 bolnikov do 5 dni, le 3 bolnike pa so zdravili do 6 dni in 2 bolnika 7 dni ali več.
Dynastat contains the active substance parecoxib.
Zdravilo Dynastat vsebuje učinkovino parekoksib.
It is not recommended to inject into an IV line delivering glucose 50 mg/ml (5%) in RingerLactate solution for injection, or other IV fluids not listed in this section, as this may cause precipitation from solution.
Ni priporočljivo, da bi zdravilo injicirali v intravensko pot, po kateri teče 50 mg/ml (5 %) glukoza v raztopini Ringerjevega laktata za injiciranje ali kakršnakoli druga intravenska tekočina, ki ni navedena v tem poglavju, ker to lahko povzroči precipitacijo iz raztopine.
There was a significantly (p<0.05) greater incidence of cardiovascular/thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/valdecoxib treatment group compared to the placebo/placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).
Pomembno večjo pojavnost (p < 0,05) kardiovaskularnih/trombemboličnih dogodkov (miokardni infarkt, ishemijo, cerebrovaskularni insult, globoko vensko trombozo in pljučno embolijo) so odkrili pri skupini, zdravljeni s parekoksibom/valdekoksibom, v primerjavi s skupino, ki je v obdobju i.v.
This medicinal product contains less than 23 mg of sodium in each dose and therefore is essentially sodium-free.
Zdravilo Dynastat vsebuje natrij To zdravilo vsebuje manj kot 23 mg natrija na odmerek, kar v bistvu pomeni 'brez natrija'.
IV line solution compatibility
Kompatibilnost v intravenski poti
The only other acceptable solvents for reconstitution are:
Kot drugi vehikel za pripravo raztopine so dovoljeni samo:
or muscle tissue.
• obarvanje kože ali modrice
Renal failure acute
Akutna ledvična odpoved
In addition to routine adverse event reporting, pre-specified event categories, adjudicated by an independent expert committee, were examined in two placebo-controlled safety studies in which patients received parecoxib for at least 3 days and then were transitioned to oral valdecoxib for a total duration of 10-14 days.
Poleg rutinskega poročanja neželenih dogodkov so v dveh s placebom nadzorovanih študijah varnosti raziskali vnaprej opredeljene kategorije pojavov, ki jih je presojal odbor neodvisnih strokovnjakov.
If you get any side effects, talk to your doctor or nurse.
Če opazite kateregakoli izmed neželenih učinkov, se posvetujte z zdravnikom ali medicinsko sestro.
BUN increased.
• povečano znojenje
Powder vial: Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium).
Viala s praškom: Ena viala vsebuje 40 mg parekoksiba (v obliki 42,36 mg natrijevega parekoksibata).
Upper gastrointestinal (GI) complications (perforations, ulcers or bleedings [PUBs]), some of them resulting in fatal outcome, have occurred in patients treated with parecoxib.
Pri bolnikih, zdravljenih s parekoksibom, so se pojavili zapleti v zgornjih prebavilih (perforacije, ulkusi ali krvavitve), ki so imeli v nekaterih primerih smrten izid.
Disodium hydrogen phosphate Phosphoric acid and/or sodium hydroxide (for pH adjustment).
Prašek natrijev hidrogenfosfat fosforjeva kislina in/ali natrijev hidroksid (za uravnavanje pH).
How to store Dynastat
Shranjevanje zdravila Dynastat
- if you have had a serious allergic reaction (especially a serious skin reaction) to any medicines - if you have had an allergic reaction to a group of medicines called “sulfonamides” (e.g. some antibiotics used to treat infections) - if you currently have a gastric or intestinal ulcer or bleeding in the stomach or gut - if you have had an allergic reaction to acetylsalicylic acid (aspirin) or to other NSAIDs (e.g.
• če ste imeli alergijsko reakcijo na skupino zdravil, imenovano “sulfonamidi” (npr. nekateri antibiotiki za zdravljenje okužb)
Caution should be used when initiating treatment with Dynastat in patients with dehydration.
Pri dehidriranih bolnikih je med uvajanjem zdravljenja z zdravilom Dynastat potrebna previdnost.
Injection into an IV line delivering glucose 50 mg/ml (5%) in Ringer-Lactate solution for injection, or other IV fluids not listed in section 6.6, is not recommended as this may cause precipitation from solution.
Injiciranje v intravensko pot, po kateri teče 50 mg/ml (5 %) glukoza v raztopini Ringerjevega laktata ali kakšna druga intravenska tekočina, ki ni navedena v poglavju 6.6, ni priporočljivo, ker lahko povzroči precipitacijo natrijevega parekoksiba iz raztopine.
Abnormal sternal serous wound drainage, wound infection Blood and lymphatic system disorders Anaemia postoperative
Bolezni krvi in limfatičnega sistema Pooperacijska anemija
Withdraw with a sterile needle and syringe, 2 ml of an acceptable solvent and insert the needle through the central portion of the rubber stopper transferring the solvent into the parecoxib 40 mg vial.
S sterilno iglo in brizgo izvlecite 2 ml dovoljenega vehikla; zabodite iglo skozi osrednji del gumijastega zamaška in prenesite vehikel v 40 mg vialo.
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or nonsteroidal antiinflammatory drugs (NSAIDs) including COX-2 inhibitors.
Bolniki, ki so po uporabi acetilsalicilne kisline ali nesteroidnih protivnetnih zdravil (NSAIDnonsteroidal anti-inflammatory drugs), vključno z zaviralci COX-2, doživeli bronhospazem, akutni rinitis, nosne polipe, angionevrotičen edem, urtikarijo ali druge alergijske reakcije.
Each vial contains 40 mg parecoxib, as 42.36 mg parecoxib sodium.
Ena viala vsebuje 40 mg parekoksiba, kar ustreza 42,36 mg natrijevega parekoksibata.
Caution should be exercised with respect to monitoring the incision for signs of infection in surgical patients receiving Dynastat.
Kirurškim bolnikom, zdravljenim z zdravilom Dynastat, je treba iz previdnosti nadzirati operacijsko rano glede prisotnosti znakov okužbe.
Thus, each 2 ml of reconstituted solution contains 40 mg of parecoxib.
Tako 2 ml rekonstituirane raztopine vsebuje 40 mg parekoksiba.
Dynastat should be introduced with caution and at half the usual recommended dose in patients with moderate hepatic impairment (Child-Pugh score 7-9) and the maximum daily dose should be reduced to 40 mg.
Pri bolnikih z zmerno okvaro jeter (ocena od 7 do 9 po Child-Pughu) pa je treba zdravljenje začeti previdno in s polovičnim običajnim priporočenim odmerkom zdravila Dynastat; maksimalni dnevni odmerek je treba zmanjšati na 40 mg.
Administration is by intramuscular (IM) or intravenous (IV) injection.
Zdravilo se aplicira kot intramuskularna (i.m.)
The magnitude of analgesic effect of the 40 mg dose was comparable with that of ketorolac 60 mg IM or ketorolac 30 mg IV. After a single dose, the duration of analgesia was dose and clinical pain model dependent, and ranged from 6 to greater than 12 hours.
Izrazitost analgetičnega učinka 40 mg odmerka je bila primerljiva tisti po 60 mg ketorolaka intramuskularno ali 30 mg ketorolaka intravensko.
• sodium chloride 9 mg/ml (0.9%) solution for injection/infusion
• 9 mg/ml (0,9 %) raztopina natrijevega klorida za injiciranje/infundiranje
Cardiovascular
Trombocitopenija
Renal function should be monitored when parecoxib and any of these medicinal products are coadministered.
Med sočasno uporabo parekoksiba s katerim od teh zdravil je treba nadzirati delovanje ledvic.
Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium).
Ena viala vsebuje 40 mg parekoksiba (v obliki 42,36 mg natrijevega parekoksibata).
Use aseptic technique to reconstitute lyophilised parecoxib (as parecoxib).
Za rekonstitucijo liofiliziranega parekoksiba (v obliki parekoksiba) uporabite aseptično tehniko.
Patients were randomized within 24-hours post-CABG surgery to: parecoxib initial dose of 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=544) for the remainder of a 10 day treatment period; placebo IV followed by valdecoxib PO (n=544); or placebo IV followed by placebo PO (n=548).
na 12 ur najmanj 3 dni, nato pa preostalih 10 dni zdravljenja še valdekoksib peroralno (20 mg na 12 ur) (n = 544); po prejemanju placeba i.v.
The IM injection is to be given slowly and deeply into the muscle and the IV bolus injection may be given rapidly and directly into a vein or into an existing IV line.
Intravensko bolusno injekcijo se lahko daje hitro in neposredno v veno ali v obstoječo intravensko pot.
• sodium chloride 9 mg/ml (0.9%) solution for injection/infusion;
• 9 mg/ml (0,9 %) raztopina natrijevega klorida za injiciranje/infundiranje;
Lithium serum concentration should be monitored closely when initiating or changing parecoxib therapy in patients receiving lithium.
Če uvedemo ali spremenimo zdravljenje s parekoksibom pri bolnikih, ki dobivajo litij, je treba koncentracijo litija v serumu natančno nadzorovati.
Reconstitution solvents Reconstitute Dynastat 40 mg with 2 ml sodium chloride 9 mg/ml (0.9%) solution.
Vehikli za rekonstitucijo Za pripravo raztopine 40 mg zdravila Dynastat uporabite 2 ml raztopine natrijevega klorida 9 mg/ml
Injection into an IV line delivering glucose 50 mg/ml (5%) in Ringer-Lactate solution for injection, or other IV fluids not listed above, is not recommended as this may cause precipitation from solution.
Injiciranje v intravensko pot, po kateri teče 50 mg/ml (5 %) glukoza v raztopini Ringerjevega laktata za injiciranje ali kakšna druga intravenska tekočina, ki ni navedena v tem poglavju, ni priporočljivo, ker lahko povzroči precipitacijo iz raztopine.
Acetylsalicyclic acid and other NSAIDs
• acetilsalicilno kislino (aspirin) ali druga protivnetna zdravila